glp-1 drugs alzheimer's Popular obesity drug fails in hotly anticipated trials | Science Can GLP-1s prevent Alzheimer's? NIH-funded

doi: 10.1007/s00125-015-3651-3 80 HervasI.QueirozC

The magnitude of the benefits of GLP-1RA and SGLT-2 inhibitors on MACE are similar, ranging from 12 to 14% reduction of risk, but only GLP-1RA may reduce the risk of stroke

Further investigation will also be needed to assess whether outcomes vary by breast cancer subtype, tumour biology, treatment history, drug type, dose, duration of use or degree of weight change

The MHRA encourages reporting of any suspected adverse drug reactions through the Yellow Card scheme (yellowcard.mhra.gov.uk)

Patients may talk about Ozempic face, characterized by the loss of facial fat

Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications approved by the FDA for treating type 2 diabetes and, in some formulations, for chronic weight management